RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer coverage changes suggests gradually increasing stringency around Ingrezza utilization, which may help explain Q4 weakness and the company’s disappointing FY25 guidance, the analyst tells investors in a research note. This may pressure both near- and longer-term demand and new patient starts more than appreciated, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- DA Davidson technology analysts hold an analyst/industry conference call
- Neurocrine assumed with an Overweight at Morgan Stanley
- Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections
- Neurocrine begins Phase 1 clinical study of NBI-1140675
- Positive Market Outlook for Neurocrine’s Crenessity Driven by Unmet Needs and Strong Physician Adoption
Questions or Comments about the article? Write to editor@tipranks.com